The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
MYC Deregulation in Primary Human Cancers
Open accessAbstract
MYC regulates a complex biological program by transcriptionally activating and repressing its numerous target genes. As such, MYC is a master regulator of many processes, including cell cycle entry, ribosome biogenesis, and metabolism. In cancer, the activity of the MYC transcriptional network is frequently deregulated, contributing to the initiation and maintenance of disease. Deregulation often leads to constitutive overexpression of MYC, which can be achieved through gross genetic abnormalities, including copy number alterations, chromosomal translocations, increased enhancer activity, or through aberrant signal transduction leading to increased MYC transcription or increased MYC mRNA and protein stability. Herein, we summarize the frequency and modes of MYC deregulation and describe both well-established and more recent findings in a variety of cancer types. Notably, these studies have highlighted that with an increased appreciation for the basic mechanisms deregulating MYC in cancer, new therapeutic vulnerabilities can be discovered and potentially exploited for the inhibition of this potent oncogene in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–249 of 249
Ryan, R. J. H., Drier, Y., Whitton, H. J., Cotton, M. J., Kaur, J., Issner, R., Gillespie, S. M., Epstein, C. B., Nardi, V., Sohani, A. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0370 · Cited by 128
Cancer whole-genome sequencing: present and future
Nakagawa, H., Wardell, C. P., Furuta, M., Taniguchi, H., & Fujimoto, A. (2015) · Oncogene · doi:10.1038/onc.2015.90 · Cited by 120
Nagl, N. G., Zweitzig, D. R., Thimmapaya, B., Beck, G. R., & Morán, E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3427 · Cited by 120
Alles, M. C., Gardiner‐Garden, M., Nott, D. J., Wang, Y., Foekens, J. A., Sutherland, R. L., Musgrove, E. A., & Ormandy, C. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004710 · Cited by 109
In vivo identification of novel STAT5 target genes
Basham, B., Sathe, M., Grein, J., McClanahan, T. K., D’Andrea, A., Lees, E., & Rascle, A. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn271 · Cited by 109
González‐Prieto, R., Cuijpers, S. A. G., Kumar, R., Hendriks, I. A., & Vertegaal, A. C. O. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1040965 · Cited by 108
Kamoun, A., Idbaïh, A., Dehais, C., Elarouci, N., Carpentier, C., Letouzé, É., Colin, C., Mokhtari, K., Jouvet, A., Uro‐Coste, E., et al. (2016) · Nature Communications · doi:10.1038/ncomms11263 · Cited by 104
Musgrove, E. A., Sergio, C. M., Loi, S., Inman, C. K., Anderson, L. R., Alles, M. C., Pinese, M., Caldon, C. E., Schütte, J., Gardiner‐Garden, M., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002987 · Cited by 101
Constitutive Activation of STAT5 by a Point Mutation in the SH2 Domain
Ariyoshi, K., Nosaka, T., Yamada, K., Onishi, M., Oka, Y., Miyajima, A., & Kitamura, T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909771199 · Cited by 101
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Berruti, A., Pia, A., & Terzolo, M. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1107198 · Cited by 101
The Mad Side of the Max Network: Antagonizing the Function of Myc and More
Rottmann, S., & Lüscher, B. (2006) · Springer eBooks · doi:10.1007/3-540-32952-8_4 · Cited by 99
Negative Control of the Myc Protein by the Stress-Responsive Kinase Pak2
Huang, Z., Traugh, J. A., & Bishop, J. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.4.1582-1594.2004 · Cited by 97
Franken, S. M., Scheidig, A. J., Krengel, U., Rensland, H., Lautwein, A., Geyer, M., Scheffzek, K., Goody, R. S., & Kalbitzer, H. R. (1993) · Biochemistry · doi:10.1021/bi00084a005 · Cited by 91
The Nerve Growth Factor-Responsive PC12 Cell Line Does Not Express the Myc Dimerization Partner Max
Hopewell, R., & Ziff, E. B. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3470 · Cited by 91
Mariani‐Costantini, R., Escot, C., Theillet, C. G., Gentile, A., Merlo, G. R., Lidereau, R., & Callahan, R. (1988) · PubMed · Cited by 91
myc gene amplification and expression in primary human neuroblastoma.
Slavc, I., Ellenbogen, R. G., Jung, W. H., Vawter, G. F., Kretschmar, C. S., Grier, H. E., & Korf, B. R. (1990) · PubMed · Cited by 90
Genetic complexity of myeloproliferative neoplasms
Královics, R. (2008) · Leukemia · doi:10.1038/leu.2008.233 · Cited by 89
Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer.
Jeruss, J. S., Sturgis, C. D., RADEMAKER, A. W., & Woodruff, T. K. (2003) · PubMed · Cited by 87
Kühn, M. W. M., Radtke, I., Bullinger, L., Goorha, S., Cheng, J., Edelmann, J., Gohlke, J., Su, X., Paschka, P., Pounds, S. B., et al. (2012) · Blood · doi:10.1182/blood-2011-09-380444 · Cited by 83
Six lysine residues on c-Myc are direct substrates for acetylation by p300
Zhang, K., Faiola, F., & Martinez, E. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.075 · Cited by 74
Inactivation of MYC reverses tumorigenesis
Li, Y., Casey, S. C., & Felsher, D. W. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12237 · Cited by 72
Miyamoto, N., Sugita, K., Goi, K., Inukai, T., Iijima, K., Tezuka, T., Kojika, S., Nakamura, M., Kagami, K., & Nakazawa, S. (2001) · Leukemia · doi:10.1038/sj.leu.2402260 · Cited by 61
Murthy, M. S., & Pande, S. V. (1990) · Biochemical Journal · doi:10.1042/bj2680599 · Cited by 60
Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-78818-0_12 · Cited by 59
Wang, H., Lu, J. L., Edmunds, L. R., Kulkarni, S., Dolezal, J. M., Tao, J., Ranganathan, S., Jackson, L. E., Fromherz, M., Beer–Stolz, D., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.754218 · Cited by 58
Cowling, V. H., Turner, S. A., & Cole, M. D. (2013) · Oncogene · doi:10.1038/onc.2013.338 · Cited by 56
Singhal, S., & Mehta, J. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03060906 · Cited by 56
Yochum, G. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018966 · Cited by 55
Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGAP interaction
Gremer, L., Gilsbach, B. K., Ahmadian, M. R., & Wittinghofer, A. (2008) · Biological Chemistry · doi:10.1515/bc.2008.132 · Cited by 54
Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma
Dolezal, J. M., Wang, H., Kulkarni, S., Jackson, L. E., Lu, J. L., Ranganathan, S., Goetzman, E. S., Bharathi, S. S., Beezhold, K., Byersdorfer, C. A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.782052 · Cited by 50
Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation
Ding, X., Yang, Y., Han, B., Du, C., Xu, N., Huang, H., Cai, T., Zhang, A., Han, Z., Zhou, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095307 · Cited by 47
MYC Phosphorylation at Novel Regulatory Regions Suppresses Transforming Activity
Wasylishen, A. R., Chan‐Seng‐Yue, M., Bros, C., Dingar, D. D., Tu, W. B., Kalkat, M., Chan, P.-K., Mullen, P. J., Huang, L., Meyer, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4063 · Cited by 46
Self-citationWnt/Myc interactions in intestinal cancer: Partners in crime
Myant, K., & Sansom, O. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.001 · Cited by 46
Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer
Pinz, S., Unser, S., & Rascle, A. (2016) · BMC Molecular Biology · doi:10.1186/s12867-016-0063-y · Cited by 46
Co-occurrence of MYC amplification and TP53 mutations in human cancer
Ulz, P., Heitzer, E., & Speicher, M. R. (2016) · Nature Genetics · doi:10.1038/ng.3468 · Cited by 46
Pinz, S., Unser, S., Buob, D., Fischer, P., Jobst, B., & Rascle, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv188 · Cited by 41
Implication of the Ubiquitin/Proteasome System in Myc-Regulated Transcription
von der Lehr, N., Johansson, S. M., & Larsson, L. (2003) · Cell Cycle · doi:10.4161/cc.2.5.484 · Cited by 40
BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities
Rizzo, D., Ruggiero, A., Amato, M., Maurizi, P., & Riccardi, R. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1214710 · Cited by 37
Myc Regulation of mRNA Cap Methylation
Cowling, V. H., & Cole, M. D. (2010) · Genes & Cancer · doi:10.1177/1947601910378025 · Cited by 36
Symonds, G. P., Hartshorn, A., Kennewell, A., O'Mara, M. A., Bruskin, A. M., & Bishop, J. M. (1989) · PubMed · Cited by 36
A common functional consequence of tumor-derived mutations within c-MYC
Chakraborty, A. A., Scuoppo, C., Dey, S., Thomas, L. R., Lorey, S. L., Lowe, S. W., & Tansey, W. P. (2014) · Oncogene · doi:10.1038/onc.2014.186 · Cited by 35
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation
Oktay, Y., Ülgen, E., Can, Ö., Akyerli, C. B., Yüksel, Ş., Erdemgil, Y., Durası, İ. M., Henegariu, O., Nanni, P., Selevsek, N., et al. (2016) · Scientific Reports · doi:10.1038/srep27569 · Cited by 34
SUMOylation of Myc-Family Proteins
Sabò, A., Doni, M., & Amati, B. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091072 · Cited by 33
Jiménez, C., Jara‐Acevedo, M., Corchete, L. A., Castillo, D., Ordóñez, G. R., Sarasquete, M. E., Puig, N., Martínez‐López, J., Prieto-Conde, I., García‐Álvarez, M., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.08.004 · Cited by 31
c-Myc Does Not Require Max for Transcriptional Activity in PC-12 Cells
Ribon, V., Leff, T., & Saltiel, A. R. (1994) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1994.1032 · Cited by 27
Identification of c-MYC SUMOylation by Mass Spectrometry
Kalkat, M., Chan, P.-K., Wasylishen, A. R., Srikumar, T., Kim, S. S., Ponzielli, R., Bazett‐Jones, D. P., Raught, B., & Penn, L. Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115337 · Cited by 24
Self-citationCoexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
Hassan, A., Dogara, L. G., Babadoko, A., Awwalu, S., & Mamman, A. (2015) · Nigerian Medical Journal · doi:10.4103/0300-1652.149177 · Cited by 19
The role of c-Myc protooncogene in chronic myelogenous leukemia.
Nieborowska-Skorska, M., Ratajczak, M. Z., Calabretta, B., & Skórski, T. (1994) · PubMed · Cited by 13
Myc Target Genes in Neoplastic Tranformation
Shim, H., Lewis, B. C., Dolde, C. E., Li, Q., Wu, C.-S., Chun, Y. S., & Dang, C. V. (1997) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-60801-8_18 · Cited by 12
Cited by
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Regulation and metabolic functions of mTORC1 and mTORC2
Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 813
MYC as a target for cancer treatment
Duffy, M. J., O'Grady, S., Tang, M., & Crown, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102154 · Cited by 514
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 397
Polyamines in cancer: integrating organismal metabolism and antitumour immunity
Holbert, C. E., Cullen, M. T., Casero, R. A., & Stewart, T. M. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00473-2 · Cited by 350
Metadata
- Authors
- Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2017-05-25
- Volume
- 8
- Issue
- 6
- Pages
- 151
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W2618573553
- Cited by
- 443
- References
- 249
- FWCI
- 14.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.